<DOC>
	<DOCNO>NCT01316848</DOCNO>
	<brief_summary>This study determine effect food pharmacokinetics ( PK ) single dose 1.5 mg tivozanib normal healthy subject .</brief_summary>
	<brief_title>A Single Center , Open-label , Randomized , Two-period Crossover Food Effect Study Single Doses Tivozanib ( AV-951 ) Healthy Subjects</brief_title>
	<detailed_description>This study open-label , randomize , two-period , crossover PK food effect study tivozanib administer orally 1.5 mg . Subjects screen eligibility 28 day prior entry study . For 2 study period , subject admit clinical research unit ( CRU ) day dose fast overnight ( approximately 10 hour ) . On morning dose 2 study period , subject receive single oral dose 1.5 mg tivozanib either fast fed state . Subjects remain CRU least 48 hour administration study drug collection serial blood sample pharmacokinetic ( PK ) analysis safety monitoring . Subjects return CRU outpatient basis collection additional blood sample 504 hour postdose .</detailed_description>
	<criteria>Males female , 18 55 year age , inclusive . Body mass index ( BMI ) within range 18.5 31.0 kg/m2 , inclusive . In good health , determine clinically significant finding medical history , physical examination , 12lead ECG , vital sign . Clinical laboratory evaluation ( include chemistry panel comprise 20 analytes [ Chem20 ; fast least 10 hour ] , complete blood count [ CBC ] , urinalysis [ UA ] exceed 2 x ULN le 2 x LLN , unless deem clinically significant Investigator . Nonsmokers ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc. , 6 month prior Screening ) , verified cotinine test Screening study period Checkin . Negative test select drug abuse Screening ( include alcohol ) study period Checkin ( include alcohol ; Appendix A ) . Negative hepatitis panel ( include hepatitis B virus surface antigen [ HBsAg ] hepatitis C virus antibody [ antiHCV ] negative human immunodeficiency virus ( HIV ) antibody screen ( Appendix A ) . Females pregnant , nonlactating , either postmenopausal least 1 year , surgically sterile ( eg , tubal ligation , hysterectomy , etc . ) least 90 day prior screen , agree use least one follow form contraception inform consent 45 day Study Completion : nonhormonal intrauterine device spermicide ; female condom spermicide ; contraceptive sponge spermicide ; diaphragm spermicide ; cervical cap spermicide ; male sexual partner agree use male condom spermicide ; sterile sexual partner ; For female , serum pregnancy test result must negative Screening study period Checkin . Male subject either sterile agree use , period inform consent 45 day follow Study Completion , 1 follow approve method contraception : double barrier method ( eg , male condom spermicide , use female sexual partner intrauterine device spermicide , female condom spermicide , contraceptive sponge spermicide , diaphragm spermicide , use cervical cap spermicide ) ; sterile sexual partner ; female sexual partner use intravaginal system ( eg , NuvaRing® ) ; partner use oral , implantable , transdermal , injectable contraceptive . Able comprehend willing sign inform consent form ( ICF ) . Significant history clinical manifestation significant metabolic/endocrine , allergic , dermatological , hepatic , renal , hematological , pulmonary , immune , cardiovascular , gastrointestinal , genitourinary , neurological , psychiatric disorder ( determined Investigator ) . History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator . History stomach intestinal surgery , nephrectomy , cholecystectomy resection would potentially alter absorption and/or excretion orally administer drug determine investigator ( appendectomy and/or hernia repair may allow ) . History presence abnormal ECG , , Investigator 's opinion , clinically significant . Diagnosis alcoholism drug addiction within 1 year prior Period 1 Checkin . Participation investigational drug study receipt investigational study drug occur within 5 halflives 30 day , whichever long prior inform consent . Use prescription medication product within 14 day prior Period 1 prior inform consent . Use overthecounter ( OTC ) , nonprescription preparation ( include vitamin , mineral , phytotherapeutic , herbal , dietary supplement , plant derive preparation ) within 7 day prior study period Checkin . Use alcohol , grapefruit , Seville orange , caffeinecontaining food , juice , beverage within 72 hour prior study period Checkin . Use known hepatic renal clearance alter agent ( eg , erythromycin , cimetidine , barbiturate , phenothiazine , herbal/plant derive preparation St. John 's Wort , etc . ) period 60 day prior informed consent ; Poor peripheral venous access . Donation blood ≥ 250 mL 30 day prior inform consent study completion , inclusive , plasma 2 week prior inform consent study completion , inclusive . Receipt blood product within 2 month prior Period 1 Checkin ; Blood pressure great 140/90 mmHg confirm repeat Screening Period 1 Checkin . Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>AV-951</keyword>
	<keyword>tivozanib</keyword>
	<keyword>healthy Subjects</keyword>
	<keyword>food Effect</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>